Clinical experiences of percutaneous cardiopulmonary support: its effectiveness and limit.
In recent years, several types of centrifugal pumps have been widely used as the main pumps for cardiopulmonary bypass (CPB) and postcardiotomy cardiac support. From April 1990 to March 1997, a percutaneous cardiopulmonary support (PCPS) system was used in 20 patients with an average age of 58 years (13 males and 7 females). They comprised 11 ischemic, 6 valvular, 2 aortic, and 1 congenital heart disease patients. Our PCPS system consists of a centrifugal pump (BioMedicus BP-80), an oxygenator, and a reservoir. The entire blood contacting surface, including that of the thin wall cannulas, is coated by heparin bonded materials. As a result of this new technology, this system can be used for the long term without systemic heparinization. No major critical thrombi were revealed inside the pumps or circuits. Of the 20 patients, 7 (35%) (Group 1) could be weaned from PCPS, and the remaining 13 (Group 2) could not. In Group 1 although 2 patients suffered from renal failure and pneumonia, respectively, both were discharged from our hospital. The long-term survival rate was 35%. In Group 2 cerebral vascular damage was recognized in 3 patients, renal failure in 4, multiple system organ failure in 4, bleeding in 2, arrhythmia in 1, and leg ischemia in 2. Pulse pressure was significantly elevated due to the recovery of the native heart in Group 1, 2 days after support. However, in Group 2, it did not elevate, and the left ventricular ejection fraction was less than 30%, associated with high left atrial pressure. In conclusion, this heparin coated PCPS system was very simple and easy to control. It demonstrated long-term biocompatibility and was very effective in recovering deteriorated cardiac function. Quicker application of this system can play an important role in preventing severe complications and obtaining better clinical results. If long-term support is necessary, a ventricular assist device (VAD), which is more powerful, durable, and biocompatible, has to be applied instead of PCPS.
Orime
Y
Y
The Second Department Surgery, Nihon University School of Medicine, Tokyo, Japan.
Shiono
M
M
Hata
H
H
Yagi
S
S
Tsukamoto
S
S
Okumura
H
H
Nakata
K
K
Kimura
S
S
Sezai
A
A
Sezai
Y
Y
D058186:Acute Kidney Injury / Q000150:complications; D000368:Aged; D000925:Anticoagulants / Q000008:administration & dosage; D001018:Aortic Diseases / Q000601:surgery; D001145:Arrhythmias, Cardiac / Q000150:complications; D001243:Assisted Circulation / Q000295:instrumentation; D001672:Biocompatible Materials; D002315:Cardiopulmonary Bypass / Q000295:instrumentation; D002404:Catheterization / Q000295:instrumentation; D002561:Cerebrovascular Disorders / Q000150:complications; D005260:Female; D006330:Heart Defects, Congenital / Q000601:surgery; D006349:Heart Valve Diseases / Q000601:surgery; D006354:Heart, Artificial; D006470:Hemorrhage / Q000150:complications; D006493:Heparin / Q000008:administration & dosage; D006801:Humans; D007511:Ischemia / Q000150:complications; D007866:Leg / Q000098:blood supply; D008297:Male; D008875:Middle Aged; D009102:Multiple Organ Failure / Q000150:complications; D017202:Myocardial Ischemia / Q000601:surgery; D010106:Oxygenators; D010351:Patient Discharge; D011014:Pneumonia / Q000150:complications; D011474:Prosthesis Design; D013318:Stroke Volume; D015996:Survival Rate; D013927:Thrombosis / Q000517:prevention & control; D016277:Ventricular Function, Left
D000925:Anticoagulants; D001672:Biocompatible Materials; D006493:Heparin